ETF Foundry
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.
investment factor · long-only model fund

Foundry Healthcare DelEqu Factor ETF

ETF Foundry Research (hypothetical) · rebalanced monthly

FDEHHYPOTHETICAL MODEL
Since ’99
+120%
Expense Ratio
0.45%
placeholder
Holdings
95
cap-weighted
Inception
Dec 2020
placeholder
Full Sharpe
0.24
Ann. Return (LS)
6.2%
Ann. Volatility
26.3%
Max Drawdown
-59.3%
Test Sharpe ’19–26
0.45
Test FF5 α (ann.)
13.1%
vs Fama-French 5
Test FF5 α t-stat
1.52
not significant
Monthly turnover
18%
of the long leg, per rebalance
Cumulative return (LS)
120%
over 331 months
This fund holds the long leg only
Long leg Sharpe
0.53
what this fund holds
Long leg ann. return
14.6%
buyable, long-only
Long-short Sharpe
0.24
requires shorting
Bottom bucket ann. return
8.4%
the basket shorted

Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.

Hypothetical growth of $1 — long-short backtest

Gross of the placeholder expense ratio and trading costs · not investor results

331 months

Holdings

Every constituent of the long leg — sort, search or filter by sector

95 of 95 · 100.0% of book
TickerCompanySectorMarket capWeight
1RVMD
REVOLUTION MEDICINES INCHealthcare$39.58B
15.77%
2MRNA
MODERNA INCHealthcare$24.53B
9.78%
3UTHR
UNITED THERAPEUTICS CORPHealthcare$22.74B
9.06%
4BBIO
BRIDGEBIO PHARMA INCHealthcare$15.94B
6.35%
5MDGL
MADRIGAL PHARMACEUTICALS INCHealthcare$12.76B
5.09%
6CYTK
CYTOKINETICS INCHealthcare$9.98B
3.98%
7HALO
HALOZYME THERAPEUTICS INCHealthcare$9.23B
3.68%
8IBRX
IMMUNITYBIO INCHealthcare$8.04B
3.21%
9CHE
CHEMED CORPHealthcare$6.77B
2.70%
10TFX
TELEFLEX INCHealthcare$5.96B
2.38%
11CELC
CELCUITY INCHealthcare$4.31B
1.72%
12VKTX
VIKING THERAPEUTICS INCHealthcare$4.31B
1.72%
13DOCS
DOXIMITY INCHealthcare$3.94B
1.57%
14RLAY
RELAY THERAPEUTICS INCHealthcare$3.81B
1.52%
15DNLI
DENALI THERAPEUTICS INCHealthcare$3.70B
1.47%
16ACHC
ACADIA HEALTHCARE COMPANY INCHealthcare$3.17B
1.26%
17RARE
ULTRAGENYX PHARMACEUTICAL INCHealthcare$2.88B
1.15%
18XRAY
DENTSPLY SIRONA INCHealthcare$2.81B
1.12%
19CLDX
CELLDEX THERAPEUTICS INCHealthcare$2.77B
1.11%
20BCRX
BIOCRYST PHARMACEUTICALS INCHealthcare$2.36B
0.94%
21AGIO
AGIOS PHARMACEUTICALS INCHealthcare$2.36B
0.94%
22BHVN
BIOHAVEN LTDHealthcare$2.32B
0.93%
23SION
SIONNA THERAPEUTICS INCHealthcare$2.23B
0.89%
24AGL
AGILON HEALTH INCHealthcare$2.17B
0.86%
25CDNA
CAREDX INCHealthcare$2.05B
0.82%
26NUVB
NUVATION BIO INCHealthcare$2.03B
0.81%
27SNDX
SYNDAX PHARMACEUTICALS INCHealthcare$2.02B
0.81%
28PLSE
PULSE BIOSCIENCES INCHealthcare$1.98B
0.79%
29URGN
UROGEN PHARMA LTDHealthcare$1.96B
0.78%
30MRVI
MARAVAI LIFESCIENCES HOLDINGS INCHealthcare$1.87B
0.75%
31ZYME
ZYMEWORKS INCHealthcare$1.77B
0.70%
32BFLY
BUTTERFLY NETWORK INCHealthcare$1.73B
0.69%
33FTRE
FORTREA HOLDINGS INCHealthcare$1.68B
0.67%
34VIR
VIR BIOTECHNOLOGY INCHealthcare$1.59B
0.63%
35NTLA
INTELLIA THERAPEUTICS INCHealthcare$1.59B
0.63%
36PRGO
PERRIGO CO PLCHealthcare$1.48B
0.59%
37MLTX
MOONLAKE IMMUNOTHERAPEUTICSHealthcare$1.45B
0.58%
38XNCR
XENCOR INCHealthcare$1.30B
0.52%
39ABSI
ABSCI CORPHealthcare$1.29B
0.52%
40INBX
INHIBRX BIOSCIENCES INCHealthcare$1.28B
0.51%
41QDEL
QUIDELORTHO CORPHealthcare$1.19B
0.47%
42MGTX
MEIRAGTX HOLDINGS PLCHealthcare$1.15B
0.46%
43EYPT
EYEPOINT INCHealthcare$1.12B
0.44%
44CGEM
CULLINAN THERAPEUTICS INCHealthcare$1.09B
0.43%
45AVTX
AVALO THERAPEUTICS INCHealthcare$1.02B
0.41%
46VOR
VOR BIOPHARMA INCHealthcare$980M
0.39%
47KURA
KURA ONCOLOGY INCHealthcare$964M
0.38%
48ANNX
ANNEXON INCHealthcare$950M
0.38%
49REPL
REPLIMUNE GROUP INCHealthcare$859M
0.34%
50CLYM
CLIMB BIO INCHealthcare$727M
0.29%
51AURA
AURA BIOSCIENCES INCHealthcare$723M
0.29%
52CBLL
CERIBELL INCHealthcare$710M
0.28%
53SPRY
ARS PHARMACEUTICALS INCHealthcare$695M
0.28%
54EVH
EVOLENT HEALTH INCHealthcare$654M
0.26%
55TECX
TECTONIC THERAPEUTIC INCHealthcare$615M
0.25%
56NGNE
NEUROGENE INCHealthcare$590M
0.24%
57MYGN
MYRIAD GENETICS INCHealthcare$584M
0.23%
58TOI
ONCOLOGY INSTITUTE INCHealthcare$535M
0.21%
59ARVN
ARVINAS INCHealthcare$517M
0.21%
60DNA
GINKGO BIOWORKS HOLDINGS INCHealthcare$517M
0.21%
61RGNX
REGENXBIO INCHealthcare$511M
0.20%
62NVCT
NUVECTIS PHARMA INCHealthcare$508M
0.20%
63NRC
NRC HEALTHHealthcare$491M
0.20%
64SGMT
SAGIMET BIOSCIENCES INCHealthcare$479M
0.19%
65PRTA
PROTHENA CORP PUBLIC LTD COHealthcare$453M
0.18%
66KYTX
KYVERNA THERAPEUTICS INCHealthcare$453M
0.18%
67CCRN
CROSS COUNTRY HEALTHCARE INCHealthcare$428M
0.17%
68STRO
SUTRO BIOPHARMA INCHealthcare$391M
0.16%
69UPB
UPSTREAM BIO INCHealthcare$382M
0.15%
70ZNTL
ZENTALIS PHARMACEUTICALS INCHealthcare$364M
0.15%
71VNDA
VANDA PHARMACEUTICALS INCHealthcare$327M
0.13%
72LYEL
LYELL IMMUNOPHARMA INCHealthcare$311M
0.12%
73TKNO
ALPHA TEKNOVA INCHealthcare$291M
0.12%
74MASS
908 DEVICES INCHealthcare$278M
0.11%
75SGHT
SIGHT SCIENCES INCHealthcare$274M
0.11%
76TRDA
ENTRADA THERAPEUTICS INCHealthcare$268M
0.11%
77SRZN
SURROZEN INCHealthcare$255M
0.10%
78RNAC
CARTESIAN THERAPEUTICS INCHealthcare$243M
0.10%
79ARTV
ARTIVA BIOTHERAPEUTICS INCHealthcare$241M
0.10%
80SMTI
SANARA MEDTECH INCHealthcare$229M
0.09%
81KPTI
KARYOPHARM THERAPEUTICS INCHealthcare$216M
0.09%
82KROS
KEROS THERAPEUTICS INCHealthcare$211M
0.08%
83FOCL
FOCAL INCHealthcare$204M
0.08%
84AMWL
AMERICAN WELL CORPHealthcare$199M
0.08%
85ARCT
ARCTURUS THERAPEUTICS HOLDINGS INCHealthcare$172M
0.07%
86RCEL
AVITA MEDICAL INCHealthcare$157M
0.06%
87AARD
AARDVARK THERAPEUTICS INCHealthcare$128M
0.05%
88PIII
P3 HEALTH PARTNERS INCHealthcare$78M
0.03%
89ACET
ADICET BIO INCHealthcare$76M
0.03%
90CLNN
CLENE INCHealthcare$76M
0.03%
91SCLX
SCILEX HOLDING COHealthcare$72M
0.03%
92EDSA
EDESA BIOTECH INCHealthcare$59M
0.02%
93MCRB
SERES THERAPEUTICS INCHealthcare$52M
0.02%
94EXOZ
EXOZYMES INCHealthcare$51M
0.02%
95TIL
INSTIL BIO INCHealthcare$50M
0.02%

Full long-leg book as of July 2026 · cap-weighted · total market cap $250.89B. Hypothetical model holdings — not a registered fund’s portfolio.

Sector Breakdown

1 sectors
Healthcare
100.0%

Portfolio Style

Size × value map of the long-leg book

95 classified
Value
Blend
Growth
Large
Mid
Small
11%2
16%4
27%5
4%6
7%9
4%5
3%24
1%7
1%7

Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 82% toward Large, 59% toward Growth. +25% unclassified (26 missing size/value). Hypothetical holdings — descriptive, not realized P&L.

Tilt over time
Size tilt82% → Large
SmallLarge
Value ↔ growth tilt59% → Growth
ValueGrowth

Capital-weighted centroid of the long leg, December 1998July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.

Constraint checks

How this book measures against the concentration and liquidity rules — as implemented here

How this book was built

These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.

Passed
6
Failed
0
Not tested
1
Independent checks
7

7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.

1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.

Reported separately — arithmetically implied

Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.

No verdict sits within 1.0pp of its limit.

Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700

Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.

Derivatives risk (Rule 18f-4)

Whether this long-only book is subject to the VaR tests at all

This assessment describes the long-only book this fund holds — the top bucket only.

Governing rule
Rule 18f-4(c)(4) limited derivatives user exception

This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.

Limited derivatives user exceptionby construction

Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.

Qualifies
Required
<= 10% of net assets
Exposure
0% of net assets
Margin
+10pp

No confidence interval: this follows from portfolio construction, not from an estimate.

Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.

Informational — does not govern

This fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.

Measured
2.0 (95% CI 1.1-2.3)
x reference VaR
Limit
2.00x
<= 2.00x reference VaR
Fund VaR
19.5%
99% / 20d
Reference
9.6%
FF5 market (mkt)

historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months

Same test, three estimators
historical
2.02x
over
parametric
1.76x
within
cornish fisher
3.09x
over · unreliable

The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.02 (fail) but Gaussian VaR gives 1.76 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.

Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.

The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.

See the long-short verdict on the factor page →

Since publication

Did the edge survive the paper coming out?

published 2005
Before publication (pre-2005)
0.20
Sharpe · 8.5% p.a.
January 1999December 2005 · 84 mo
Since publication
0.29
Sharpe · 5.4% p.a.
January 2006July 2026 · 247 mo
Change in Sharpe+0.09Sharpe strengthened since publication

Annual return moved the other way (3.1pp), so Sharpe and return disagree here — the change is partly a shift in volatility rather than in return.

Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.

Consistency across eras

Is this record broadly durable, or one regime?

26 windows
Positive windows
65%
17 of 26 3-year windows made money
Worst window
-0.81
Sharpe, January 2007 – December 2009
January 1999July 2026
Median Sharpe
0.16
Dispersion
0.41
Best window
0.92

3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.

Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.

Returns

Long leg is what this fund holds — long-short is shown for reference

since January 1999
Trailing
PeriodLong legLong-short
1 yearcum.87.2%42.6%
3 yearsp.a.29.3%13.5%
5 yearsp.a.10.5%15.9%
10 yearsp.a.13.2%7.9%
Since inceptionp.a.11.7%2.9%
Calendar years
YearLong legLong-short
20267 mo27.8%18.5%
202547.1%25.8%
202419.4%4.3%
20232.0%-6.6%
2022-22.2%17.4%
20211.7%37.6%
202029.5%-20.8%
201926.5%-3.3%
20180.8%10.7%
201735.6%14.8%
2016-15.3%-1.2%
201511.9%-9.5%
201430.1%-3.5%
201352.6%8.0%
201230.5%15.7%
20116.3%0.9%
201018.8%15.3%
200919.1%-12.4%
2008-30.8%-17.8%
2007-0.8%-6.9%
20063.2%11.9%
20054.0%-3.8%
2004-11.0%-14.0%
200357.1%9.9%
2002-47.2%-17.7%
2001-1.6%4.5%
200099.4%39.5%
199933.6%-5.9%

Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.

Fund Facts

Ticker (pseudo)FDEH
IssuerETF Foundry Research (hypothetical)
SeriesHypothetical Model Portfolio Series (not a registered trust)
Expense ratio0.45% (placeholder)
Inception2020-12-16 (placeholder)
Listing exchangeNot listed (hypothetical)
CUSIPNot applicable (hypothetical model portfolio)
RebalanceMonthly
Holdings as ofJuly 2026
Total mkt cap (long leg)$250.89B

Methodology

The Foundry Healthcare DelEqu Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DelEqu signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.

This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.

Documents (draft — hypothetical)

Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.

Summary Prospectus

Objective, fees, strategy, and key risks.

View →
Prospectus

Full strategy, model methodology, and risks.

View →
Statement of Additional Information

Policies, construction, and governance.

View →
Fact Sheet

One-page snapshot with top holdings.

View →
Daily Holdings

Full current constituent list.

View →

DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.